China's Hengrui launches Luzsana with Big Pharma veterans

With a unique operating model, the Hengrui subsidiary aims to “quantifiably reduce costs” of medicines, its CEO said.

Related Keywords

,Jiangsu Hengrui Medicine ,Luzsana Biotechnology ,China ,Drug Prices ,Pd 1 L1 ,Market Access ,Market Access Strategies ,Antibody Drug Conjugates ,Asia ,Executives ,Manufacturing ,Marketing ,Fierce Pharma Homepage ,Pharma ,